- βOmnipod 5 is the only tubeless AID system and the only one FDA-approved for type 2 diabetes
- βMiniMed 780G achieves the lowest glucose target (100 mg/dL) with TIR exceeding 79% in optimal users
- βControl-IQ+ has the strongest long-term real-world evidence base from the T1D Exchange Quality Improvement Collaborative
The AID Revolution: Where We Are in 2025
Automated insulin delivery (AID) systems have fundamentally changed type 1 diabetes management β and increasingly, type 2. By 2025, three systems dominate the market: Insulet's Omnipod 5, Tandem's Control-IQ+, and Medtronic's MiniMed 780G. Each uses a different algorithm, different hardware philosophy, and targets a slightly different patient profile. Choosing between them isn't about finding the "best" system β it's about finding the best fit.
The Systems at a Glance
Omnipod 5 is the only tubeless option in this class. The pod adheres directly to the skin and communicates with a smartphone app (iOS and Android) or a dedicated handheld controller. It uses a Horizon algorithm developed with significant input from academic partners including the University of Virginia. The SECURE-T1D pivotal trial demonstrated mean Time in Range (TIR) of approximately 74% in adults and 67% in children aged 2β5, with A1c reductions of around 0.5β0.8 percentage points across age groups.
Control-IQ+ (the updated 2024β2025 iteration of Tandem's original Control-IQ) pairs with Dexcom CGM and uses a model predictive control (MPC) algorithm. The original Control-IQ pivotal trial (PROLOG) published in The New England Journal of Medicine in 2019 showed TIR improvement from 61% to 71% versus standard therapy. The updated Control-IQ+ firmware, rolled out through 2024, added enhanced hypoglycemia prediction and sleep activity detection. Real-world data from the T1D Exchange Quality Improvement Collaborative continues to show Control-IQ among the strongest performers in TIR metrics across diverse populations.
MiniMed 780G from Medtronic is the most aggressive automated system currently available in the U.S., offering a target glucose as low as 100 mg/dL β lower than either competitor. The ADAPT trial and international ANSWER-ON study demonstrated mean TIR exceeding 79% in optimal users, with A1c reductions averaging 0.7 percentage points. The 780G works with Medtronic's own Guardian 4 CGM sensor, which now requires zero fingerstick calibrations. However, real-world U.S. adoption has been tempered by Medtronic's historically complex infusion set ecosystem and a learning curve with automode optimization.
Head-to-Head: What the Data Actually Shows
No large randomized controlled trial has directly compared all three systems simultaneously in the same population β a limitation patients should understand. Most comparisons draw on parallel real-world registries and separate pivotal trials with different enrollment criteria.
A 2023 meta-analysis published in Diabetes Care comparing AID systems across multiple trials found that systems with lower glucose targets (like the 780G) generally achieved higher TIR, but with modestly more time spent in hypoglycemia in some subgroups. The Omnipod 5 consistently showed the strongest data in pediatric populations and in patients new to insulin pump therapy. Control-IQ demonstrated strong performance in adults with established pump experience.
The ongoing FLAIR trial (Fuzzy Logic Automated Insulin Regulation), originally comparing MiniMed 670G to Control-IQ, has informed subsequent design comparisons. More relevant to 2025, the T1D Exchange and Jaeb Center for Health Research continue to publish real-world comparative effectiveness data through their Autoimmune Diabetes Data Exchange (ADDE) β the most current head-to-head real-world comparison available.
Key Differences That Matter to Patients
- Tubing vs. tubeless: Omnipod 5 is the only tubeless option β significant for swimmers, athletes, and those who dislike visible tubing.
- CGM compatibility: Omnipod 5 works with Dexcom G6 and G7. Control-IQ+ requires Dexcom G7. MiniMed 780G requires Medtronic Guardian 4.
- Smartphone control: Omnipod 5 offers full smartphone control. Control-IQ+ and 780G offer companion apps but require dedicated pumps for primary dosing.
- Target glucose flexibility: MiniMed 780G allows the lowest target (100 mg/dL). Control-IQ+ targets 110 mg/dL. Omnipod 5 targets 110 mg/dL in standard mode.
- Type 2 diabetes approval: Omnipod 5 received FDA approval for type 2 diabetes in 2023 β a major differentiator. The SECURE-T2D trial demonstrated meaningful A1c reduction in type 2 patients. The 780G and Control-IQ+ remain primarily indicated for type 1.
Current Status (2025)
All three systems are FDA-approved and commercially available in the United States. Omnipod 5 has the broadest age and diagnosis approval (type 1 and type 2, ages 2 and up). Control-IQ+ is approved for type 1, ages 6 and up. MiniMed 780G is approved for type 1, ages 7 and up.
Insurance coverage varies significantly. Medicare covers all three systems but with different supply requirements. Patients sourcing supplies through providers like mdsdiabetes.com can compare formulary and out-of-pocket costs, which remain a real-world barrier for many patients regardless of which system performs best in trials.
Medtronic's next-generation system (MiniMed 780G successor) and Tandem's Mobi pump with Control-IQ+ are both in various stages of expanded rollout. Insulet has announced Omnipod 5 algorithm updates targeting tighter overnight control.
What This Means for Patients
The honest answer is that all three systems meaningfully outperform multiple daily injections for most people with type 1 diabetes. The differences between them are real but moderate for the average patient. Your choice should be driven by lifestyle factors (tubeless vs. tubed), your preferred CGM, your insurance formulary, and your healthcare team's experience with each system.
Patients with type 2 diabetes should specifically ask about Omnipod 5 β it is the only AID system currently indicated for this population. For those interested in research comparisons or trial participation, ClinicalTrials.gov lists ongoing AID comparative studies under search terms "automated insulin delivery" and "closed loop".
Work with an endocrinologist or certified diabetes care and education specialist (CDCES) before switching systems β the transition period matters, and optimization takes weeks, not days.